Boston Scientific Corp. artificially inflated its stock price by touting growth in key product segments that it knew was unsustainable, leading to a disappointing revenue report and a significant stock drop, an investor alleges.
In particular, the medical device maker and its top executives flagged its US electrophysiology business unit as having a strong growth trajectory, John Troike says. Troike filed his proposed class action Thursday in the US District Court for the District of Massachusetts.
But that unit, which “develops and manufactures products used in the detection and treatment of heart rate and rhythm disorders,” had disappointing Q4 and ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.